5-溴-呋喃并[2,3-b]吡啶 | 220957-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡啶类
• 中文名称: 5-溴-呋喃并[2,3-b]吡啶
• 中文别名: 5-溴呋喃并[2,3-b]吡啶；5-溴呋喃并[2,3-B]吡啶
• 英文名称: 5-bromofuro[2,3-b]pyridine
• CAS: 220957-39-1
• 化学式: C₇H₄BrNO
• mdl: MFCD16628264
• 分子量: 198.019
• InChiKey: ILFJFOMSHYIUTA-UHFFFAOYSA-N

物化性质

• 沸点：
  226℃
• 密度：
  1.710
• 闪点：
  91℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 海关编码：
  2934999090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 5-Bromofuro[2,3-B]Pyridine
: ADE001191
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 198,02 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
5-Bromofuro[2,3-B]Pyridine
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
5-Bromofuro[2,3-B]Pyridine
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-呋喃并[2,3-b]吡啶 在 tris-(dibenzylideneacetone)dipalladium(0) 、 N-氯代丁二酰亚胺 、 溶剂黄146 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 水 、 甲苯 为溶剂， 反应 0.33h， 生成 furo[2,3-b]pyridine-5-sulfonyl chloride
  参考文献：
  名称：

  [EN] PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS
  [FR] PYRROLIDINE-PYRAZOLES EN TANT QU'ACTIVATEURS DE LA PYRUVATE KINASE

  摘要：

  本文描述的主题是针对式I的丙酮酸激酶激活化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物以及用于治疗与PKR和/或PKM2相关疾病的化合物的给药方法，例如丙酮酸激酶缺乏症、镰状细胞病和β地中海贫血。

  公开号：

  WO2021202796A1
• 作为产物：
  描述：

  呋喃并[2,3-b]吡啶-5-胺 在 氢溴酸 、 copper(I) bromide 、 sodium nitrite 作用下， 生成 5-溴-呋喃并[2,3-b]吡啶
  参考文献：
  名称：

  呋喃吡啶。XXV †。5-取代的呋喃[2,3- b ]吡啶的合成

  摘要：

  通过Sandmeyer反应，由5-硝基化合物1制备在环氮的β位具有取代基的呋喃[2,3- b ]吡啶衍生物（2-8）。

  DOI：

  10.1002/jhet.5570350611

文献信息

• One-pot palladium-catalyzed synthesis of sulfonyl fluorides from aryl bromides
  作者：Alyn T. Davies、John M. Curto、Scott W. Bagley、Michael C. Willis

  DOI：10.1039/c6sc03924c

  日期：——

  A mild, efficient synthesis of sulfonyl fluorides from aryl and heteroaryl bromides utilizing palladium catalysis is described. The process involves the initial palladium-catalyzed sulfonylation of aryl bromides using DABSO as an SO2 source, followed by in situ treatment of the resultant sulfinate with the electrophilic fluorine source NFSI. This sequence represents the first general method for the

  描述了利用钯催化从芳基和杂芳基溴化物温和有效地合成磺酰氟的方法。该方法涉及使用DABSO作为SO 2源进行钯催化的芳基溴的磺化反应，然后进行原位反应。用亲电子氟源NFSI处理所得的亚磺酸盐。该序列代表了芳基溴化物磺酰化的第一种通用方法，并为先前描述的磺酰氟合成提供了实用的一锅替代品，从而可以快速使用这些生物学上重要的分子。证明了优异的官能团耐受性，并且成功地在多种活性药物成分及其前体上实现了转化。还证明了肽衍生的磺酰氟的制备。
• Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation
  作者：Chengbin Yang、Chenyue Xu、Zhipeng Li、Yi Chen、Tianze Wu、Hui Hong、Mingzhu Lu、Yu Jia、Yongtai Yang、Xiaofeng Liu、Mingli Deng、Zhenxia Chen、Qingquan Li、Yun Ling、Yaming Zhou

  DOI：10.1016/j.ejmech.2021.113661

  日期：2021.11

  Based on indole scaffold, a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, namely FD223, was developed by the bioisosteric replacement drug discovery approach and studied for the treatment of acute myeloid leukemia (AML). In vitro studies revealed that FD223 displays high potency (IC50 = 1 nM) and selectivity (29–51 fold over other PI3K isoforms) against PI3Kδ, and exhibits

  基于吲哚支架，一种有效的选择性磷酸肌醇 3-激酶δ (PI3K δ ) 抑制剂，即FD223，是通过生物等排替代药物发现方法开发的，并研究用于治疗急性髓系白血病 (AML)。体外研究表明，FD223 对 PI3K δ显示出高效力 (IC 50 = 1 nM) 和选择性（比其他 PI3K 异构体高 29-51 倍），并显示出对 AML 细胞系（MOLM-16、HL- 60、EOL-1 和 KG-1）通过抑制 p-AKT Ser473 从而导致细胞周期中的 G1 期停滞。进一步考虑到FD223的有利药代动力学 (PK) 特征，在体内在裸鼠中使用异种移植模型对研究进行了评估，证实了其显着的抗肿瘤功效，同时没有可观察到的毒性。所有这些结果都与 Idelalisib (CAL-101) 的阳性组相当，表明FD223作为一种有前景的 PI3K δ抑制剂有潜力进一步发展，用于治疗白血病等白血病。
• [EN] PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS<br/>[FR] DÉRIVÉS PYRAZOLO[1, 5-A]PYRIMIDINE EN TANT QU'INHIBITEURS DE MTOR
  申请人：SCHERING CORP

  公开号：WO2010118207A1

  公开（公告）日：2010-10-14

  The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.

  本发明提供了使用吡唑并[1,5-a]嘧啶化合物抑制 mTOR 的方法，以及利用这些化合物治疗、预防、抑制或改善与 mTOR 相关的一种或多种疾病的方法。
• Pharmaceutical compositions and methods for use
  申请人：——

  公开号：US20020058652A1

  公开（公告）日：2002-05-16

  The present invention relates to aryl olefinic azacyclic compounds and aryl acetylenic azacyclic compounds, including pyridyl olefinic cycloalkylamines and pyridyl acetylenic cycloalkylamines. The present invention also relates to prodrug derivatives of the compounds of the present invention.

  本发明涉及芳基烯丙基氮杂环化合物和芳基炔丙基氮杂环化合物，包括吡啶基烯丙基环烷基胺和吡啶基炔丙基环烷基胺。本发明还涉及本发明化合物的药物前体衍生物。
• [EN] PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE<br/>[FR] COMPOSITIONS PHARMACEUTIQUES ET METHODES D'UTILISATION
  申请人：TARGACEPT INC

  公开号：WO2000075110A1

  公开（公告）日：2000-12-14

  Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (2S)-(4E)-N-methyl-5-[3-(5-isopropoxy-1-oxopyridin)yl)]-4-penten-2-amine, (3E)-N-methyl-4-(3-(1-oxopyridin)yl)-3-buten-1-amine, (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-((carboxymethyl)oxy)pyridin)yl)-4-penten-2-amine, (3E)-N-methyl-4-[3-(5-nitro-6-aminopyridin)yl]-3-buten-1-amine, (3E)-N-methyl-4-[3-(5-(N-benzylcarboxamido)pyridin)yl]-3-buten-1-amine(4E)-N-methyl-5-[5-(2-aminopyrimidin)yl]-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-aminopyridin)yl)-4-penten-2-amine (3E)-N-methyl-4-(3-(5-isobutoxypyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(5-ethylthiopyridin)yl)-3-buten-1-amine, (4E)-N-methyl-5-(3-(5-trifluoromethylpyridin)yl)-4-penten-2-amine, (4E)-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, and (4E)-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine.

  制药组合物包括芳基取代烯丙胺化合物。代表性化合物有(2S)-(4E)-N-甲基-5-[3-(5-异丙氧基-1-氧代吡啶)基)]-4-戊烯-2-胺，(3E)-N-甲基-4-(3-(1-氧代吡啶)基)-3-丁烯-1-胺，(4E)-N-甲基-5-(3-(1-氧代吡啶)基)-4-戊烯-2-胺，(4E)-N-甲基-5-(3-(5-((羧甲基)氧基)吡啶)基)-4-戊烯-2-胺，(3E)-N-甲基-4-[3-(5-硝基-6-氨基吡啶)基]-3-丁烯-1-胺，(3E)-N-甲基-4-[3-(5-(N-苯甲酰基)吡啶)基]-3-丁烯-1-胺，(4E)-N-甲基-5-[5-(2-氨基嘧啶)基]-4-戊烯-2-胺，(4E)-N-甲基-5-(3-(5-氨基吡啶)基)-4-戊烯-2-胺，(3E)-N-甲基-4-(3-(5-异丁氧基吡啶)基)-3-丁烯-1-胺，(3E)-N-甲基-4-(3-(5-乙硫基吡啶)基)-3-丁烯-1-胺，(4E)-N-甲基-5-(3-(5-三氟甲基吡啶)基)-4-戊烯-2-胺，(4E)-5-(3-(5-异丙氧基吡啶)基)-4-戊烯-2-胺，以及(4E)-5-(3-(5-异丙氧基吡啶)基)-4-戊烯-2-胺。